Neurology Central

Recurrent ganglioglioma in adults treated with BRAF inhibitors


Thirteen adult patients with temozolomide, surgery and radiation refractory ganglioglioma were screened for the BRAF V600E mutation. Three (23%) were found positive for the presence of the BRAF mutation and were treated with the BRAF inhibitor dabrafenib. Dabrafenib was well tolerated with no grade 3 or higher toxicity.

To view restricted content, please:

Leave A Comment